7.02
-6.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cartesian Therapeutics
From its filings with the US Securities and Exchange Commission
Cartesian Therapeutics is based in Frederick, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RNAC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.8m and a net loss of $130.3m. At that date it held total assets of $296.4m and shareholders' equity of −$126.2m.
The Company (formerly known as Selecta Biosciences, Inc., or Selecta) was incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland. On November 13, 2023, the Company and the Delaware corporation which, immediately prior to the Merger (as defined below), was known as Cartesian Therapeutics, Inc., or Old Cartesian, entered into an Agreement and Plan of Merger, or the Merger Agreement, by and among the Company, Sakura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, or First Merger Sub, Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, and simultaneously with execution thereof, (i) First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation, or the First Step Surviving Corporation, and became a wholly owned subsidiary of the Company, or the First Merger, and (ii) immediately following the First Merger, Old Cartesian (as the First Step Surviving Corporation) merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving company, or the Surviving Company, and continued under the name “Cartesian Bio, LLC”, or the Second Merger and, together with the First Merger, the Merger. In connection with the Merger and pursuant to the Merger Agreement, the Company (which was known as Selecta Biosciences, Inc.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Jun 2016
- Employees
- 75
- Website
- selectabio.com ↗
- Head office
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Carrie CoxIndependent Chairman of the Board$331,366
- Dr. Carsten BrunnPresident, Chief Executive Officer, Director, since 2018$7.3m
- Mr. Blaine DavisChief Financial Officer$4.0m
- Dr. Emily EnglishChief Operations Officer
- Dr. Chris JewellChief Scientific Officer$1.7m
- Dr. Milos MiljkovicChief Medical Officer
- Dr. Timothy SpringerDirector$277,332
- Mr. Timothy BarabeIndependent Director$291,522
- Dr. Nishan de SilvaIndependent Director$284,967
- Dr. Murat KalayogluIndependent Director$280,806
- Dr. Kemal MalikIndependent Director$314,568
- Dr. Michael SingerIndependent Director$281,028
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 71
- Environment
- 76
- Social
- 76
- Governance
- 60
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Descartes-08 is in Phase IIb clinical development for generalized myasthenia gravis treatment.
- Descartes-08 has Orphan Drug Designation from the FDA for myasthenia gravis.
- RNA Armory platform enables precision control of engineered cells for diverse therapies.
Weaknesses
- Company has 75 employees in Watertown, Massachusetts.
- Descartes-08 is in Phase IIb clinical development stage.
- Company went public on 22 June 2016.
Opportunities
- RNA Armory platform supports autologous, allogeneic, and in vivo transfection modalities.
- Descartes-08 targets autoimmune diseases including myasthenia gravis.
- US FDA Orphan Drug Designation provides regulatory advantage for Descartes-08.
Threats
- Descartes-08 is in Phase IIb clinical development for myasthenia gravis.
- Company has 75 employees in Watertown, Massachusetts.
- Descartes-08 is a clinical-stage biopharmaceutical product.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.